Osaka, Japan

Nobutoshi Matsushita

This inventor holds 1 USPTO granted patent. Top assignee: Rohto Pharmaceutical Co., Ltd.. Active years: 2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nobutoshi Matsushita. Retrieved from https://idiyas.com/inventor/nobutoshi-matsushita

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Nobutoshi Matsushita: Innovator in Ophthalmic Compositions

Introduction

Nobutoshi Matsushita is a prominent inventor based in Osaka, Japan. He is known for his significant contributions to the field of ophthalmology, particularly through his innovative patent related to ophthalmic compositions.

Latest Patents

Matsushita holds a patent for ophthalmic compositions that have negligible side effects on the heart. The active ingredient in these compositions is an adrenergic β receptor agonist that exhibits high selectivity toward adrenergic β receptors. These compositions are designed to be used as preventives or therapeutics for xerophthalmic disorder and keratoconjunctival disorder. He has 1 patent to his name.

Career Highlights

Matsushita has made a notable impact in the pharmaceutical industry through his work at Rohto Pharmaceutical Co., Ltd. His research and development efforts have led to advancements in treatments for eye-related disorders, showcasing his dedication to improving patient care.

Collaborations

Throughout his career, Matsushita has collaborated with esteemed colleagues, including Yoichi Honma and Yukie Akagi. These partnerships have contributed to the success of his projects and the advancement of ophthalmic research.

Conclusion

Nobutoshi Matsushita is a key figure in the development of innovative ophthalmic compositions. His work continues to influence the field and improve the quality of life for individuals suffering from eye disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…